HCM
BMRN icon

Highbridge Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Highbridge Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-20,000
Closed -$1.65M – 1411
2016
Q1 		$1.65M Buy
+20,000
New +$1.63M 0.03% 570

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Highbridge Capital Management's BMRN Position: Q4 2017 in Review

Highbridge Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2017, closing a stake of 103,300 shares — an estimated $9.61M sold.

Highbridge Capital Management first reported a position in BMRN in Q2 2013 and held it in 11 quarters. The position peaked at $10.8M in Q3 2016. 438 funds tracked by Wall St. Rank hold BMRN as of Q4 2017.

  • Highbridge Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Highbridge Capital Management sold 103,300 BioMarin Pharmaceuticals shares in Q4 2017, an estimated $9.61M.
  • Highbridge Capital Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 11 quarters.
  • Highbridge Capital Management's BioMarin Pharmaceuticals position peaked at $10.8M in Q3 2016.
  • 438 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2017.

Based on Highbridge Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.